Harmine promotes osteoblast differentiation through bone morphogenetic protein signaling

Biochemical and Biophysical Research Communications

Volumn 409, Issue 2, 2011, Pages 260-265

  Yonezawa, Takayuki ^a,b   Lee, Ji Won ^b   Hibino, Ayaka ^b   Asai, Midori ^b   Hojo, Hironori ^c   Cha, Byung Yoon ^b   Teruya, Toshiaki ^b,d   Nagai, Kazuo ^b   Chung, Ung Il ^c   Yagasaki, Kazumi ^a,e   Woo, Je Tae ^a,b  

^a UNIVERSITY OF TOKYO   (Japan)

^b CHUBU UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d UNIVERSITY OF THE RYUKYUS   (Japan)

^e TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Japan)

Author keywords

Bone morphogenetic protein; Harmine; Natural small molecule; Osteoblast

Indexed keywords

ALKALINE PHOSPHATASE; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN 6; DORSOMORPHIN; HARMALINE; HARMALOL; HARMAN; HARMINE; HARMOL; MESSENGER RNA; NOGGIN; OSTEOCALCIN; OSTEOGENIC PROTEIN 1; PROTEIN TYROSINE KINASE INHIBITOR; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BIOSYNTHESIS; BONE DEVELOPMENT; BONE MATRIX; BONE MINERALIZATION; CALVARIA; CELL DIFFERENTIATION; CELL PROLIFERATION; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG STRUCTURE; MARKER GENE; MESENCHYMAL STEM CELL; MOUSE; NEWBORN; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

ANIMALS; BONE MORPHOGENETIC PROTEINS; CARBOLINES; CELL DIFFERENTIATION; CELL LINE; CORE BINDING FACTOR ALPHA 1 SUBUNIT; GENE EXPRESSION; HARMINE; HUMANS; INHIBITOR OF DIFFERENTIATION PROTEIN 1; MICE; MICE, INBRED STRAINS; OSTEOBLASTS; OSTEOGENESIS; SIGNAL TRANSDUCTION; SKULL; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSCRIPTION FACTORS;

EID: 79957918508     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.05.001     Document Type: Article

References (20)

1. Rodan G.A., Martin T.J. Therapeutic approaches to bone diseases. Science 2000, 289:1508-1514.
2. Harada S., Rodan G.A. Control of osteoblast function and regulation of bone mass. Nature 2003, 423:349-355.
3. Yamaguchi A., Komori T., Suda T. Regulation of osteoblast differentiation mediated by bone morphogenetic proteins, hedgehogs, and Cbfa1. Endocr. Rev. 2000, 21:393-411.
4. Miyazono K., Maeda S., Imamura T. BMP receptor signaling: transcriptional targets, regulation of signals, and signaling cross-talk. Cytokine Growth Factor Rev. 2005, 16:251-263.
5. Canalis E., Economides A.N., Gazzerro E. Bone morphogenetic proteins, their antagonists, and the skeleton. Endocr. Rev. 2003, 24:218-235.
6. Ducy P., Zhang R., Geoffroy V., Ridall A.L., Karsenty G. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 1997, 89:747-754.
7. Komori T., Yagi H., Nomura S., Yamaguchi A., Sasaki K., Deguchi K., Shimizu Y., Bronson R.T., Gao Y.H., Inada M., Sato M., Okamoto R., Kitamura Y., Yoshiki S., Kishimoto T. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997, 89:755-764.
8. Otto F., Thornell A.P., Crompton T., Denzel A., Gilmour K.C., Rosewell I.R., Stamp G.W., Beddington R.S., Mundlos S., Olsen B.R., Selby P.B., Owen M.J. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 1997, 89:765-771.
9. Nakashima K., Zhou X., Kunkel G., Zhang Z., Deng J.M., Behringer R.R., de Crombrugghe B. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 2002, 108:17-29.
10. Marie P.J. Transcription factors controlling osteoblastogenesis. Arch. Biochem. Biophys. 2008, 473:98-105.
11. Axelrad T.W., Einhorn T.A. Bone morphogenetic proteins in orthopaedic surgery. Cytokine Growth Factor Rev. 2009, 20:481-488.
12. Garrett I.R. Anabolic agents and the bone morphogenetic protein pathway. Curr. Top. Dev. Biol. 2007, 78:127-171.
13. Allen J.R.F., Holmstedt B.R. The simple β-carboline alkaloids. Phytochemistry 1980, 19:1573-1582.
14. Cao R., Peng W., Wang Z., Xu A. β-Carboline alkaloids: biochemical and pharmacological functions. Curr. Med. Chem. 2007, 14:479-500.
15. Waki H., Park K.W., Mitro N., Pei L., Damoiseaux R., Wilpitz D.C., Reue K., Saez E., Tontonoz P. The small molecule harmine is an antidiabetic cell-type-specific regulator of PPARγ expression. Cell Metab. 2007, 5:357-370.
16. Berrougui H., Martin-Cordero C., Khalil A., Hmamouchi M., Ettaib A., Marhuenda E., Herrera M.D. Vasorelaxant effects of harmine and harmaline extracted from Peganum harmala L. seeds in isolated rat aorta. Pharmacol. Res. 2006, 54:150-157.
17. Yonezawa T., Hasegawa S., Asai M., Ninomiya T., Sasaki T., Cha B.Y., Teruya T., Ozawa H., Yagasaki K., Nagai K., Woo J.T. Harmine, a β-carboline alkaloid, inhibits osteoclast differentiation and bone resorption in vitro and in vivo. Eur. J. Pharmacol. 2011, 650:511-518.
18. Takahashi N., Udagawa N., Kobayashi Y., Suda T. Generation of osteoclasts in vitro, and assay of osteoclast activity. Methods Mol. Med. 2007, 135:285-301.
19. Kusanagi K., Inoue H., Ishidou Y., Mishima H.K., Kawabata M., Miyazono K. Characterization of a bone morphogenetic protein-responsive Smad-binding element. Mol. Biol. Cell 2000, 11:555-565.
20. Ducy P., Karsenty G. Two distinct osteoblast-specific cis-acting elements control expression of a mouse osteocalcin gene. Mol. Cell. Biol. 1995, 15:1858-1869.